exalt® is a DeepTech spin-off and develops a functional precision oncology test which directly measures how individual patients’ cancer cells respond directly  to >130 cancer therapies. By testing living tumor cells ex vivo, our technology identifies effective treatments on tumor cells while sparing healthy cells. Our team demonstrated with this approach a clear clinical benefit for late-stage cancer patients. exalt® envisions a future where therapy decisions are guided by real cancer cell responses of patients, rather than probabilities, making personalized, evidence-based cancer care the new standard. exalt® empowers oncologists with actionable insights and transforms oncology into a precise, patient-specific science. This builds a new paradigm shift in cancer care.